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Abstract
Bcl-3 is an atypical member of the inhibitor of NF-kappa B family of proteins since it can function as a coactivator
of transcription. Although this oncogene was described in leukemia, it is overexpressed in a number of solid
tumors as well. The oncogenic potential of Bcl-3 has been associated with its capacity to increase proliferation by
means of activating the cyclin D1 promoter and to its antiapoptotic role mediated by the inhibiton of p53 activity.
In the course of dissecting these properties, we found that depleting Bcl-3 protein using shRNAs induce a decrease
of proliferation and clonogenic survival associated with the induction of multinucleation and increased ploidy.
These effects were associated with a DNA damage response, a delay in G2/M checkpoint and the induction of
centrosome amplification
Findings
The Bcl-3 oncogene was first identified in a subset of
patients with chronic lymphocytic leukemia (CLL) in the
region adjacent to the t(14;19)(q32;q13) translocation
[1,2]. Bcl-3 is a member of the NF-kappa B inhibitor
family, which includes I-kappa B alpha, beta, epsilon
and zeta. NF-kappa B is a pleiotropic transcription fac-
tor involved in several physiological and pathological
processes such as inflammation, immune response and
cancer. NF-kappa B inhibitory proteins act to suppress
NF-kappa B activity by blocking the nuclear transloca-
tion of this factor, thus preventing the transcription of
target genes. The protein encoded by Bcl-3 is atypical
among inhibitory proteins because it is able to activate
transcription [3-5]. This effect is mediated by its associa-
tion with the NF-kappa B homodimers, p50 and p52,
along with coactivators such as CBP/p300, SRC-1 and
Tip60 [4,6]. While Bcl-3 overexpression was originally
found to be associated with CLL and lymphomas, recent
reports have shown that this oncogene is overexpressed
in several solid tumors, such as breast [7], nasopharyn-
geal [8] and endometrial [9] carcinomas.
Although some advances have been made in defining
the cellular and molecular effects of Bcl-3, its precise
role in carcinogenesis is still unclear. Earlier work by
Westerheide et al. showed that in breast epithelial cells,
Bcl-3 is able to act as a coactivator with NF-kappa B
p52 homodimers to directly activate the cyclin D1 pro-
moter, so direct effects on the cell cycle could be
responsible for its oncogenic effects [10]. Also support-
ing this line of evidence is the finding that the tumor
suppressor CYLD blocks cyclin D1 expression by inhi-
biting Bcl-3 signaling [11]. An additional role for Bcl-3
in carcinogenesis has recently been suggested by Kasha-
tus et al., who demonstrated that after DNA damage,
Bcl-3 is required for the induction of Hdm2 gene
expression and the suppression of persistent p53 activity
[12]. These results suggest that the oncogenic role of
Bcl-3 could be mediated by a p53-dependent pathway,
possibly by preventing the apoptosis of cells with
damaged DNA.
In order to dissect the contribution of apoptosis and
proliferation to the oncogenic effects of Bcl-3, we pro-
duced stable cell lines expressing small-interfering RNAs
(siRNAs) directed toward the oncoprotein (Fig. 1a and
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any medium, provided the original work is properly cited.Additional file 1, Fig. S1). As expected, based on the
previously mentioned reports, downregulation of Bcl-3
levels had a significant negative impact on the growth of
these cells. Fig 1b shows a significative reduction in the
number of Bcl-3 knockdown cells in a time course
experiment (Fig. 1b). In addition, a clonogenic assay,
which assesses the reproductive success of the cells,
showed a 40% decrease in the number of colonies
formed (Fig. 1c). Since the decrease in cellular growth
and reproductive efficiency could also be due to cell
death, we measured the rate of spontaneous apoptosis
via annexin V (not shown) and TUNEL assays. Interest-
ingly, we did not observe differences in apoptotic rates
between cells with down regulated Bcl-3 and the control
cells (Additional file 2, Fig. S2). This is an unexpected
finding, since it has been shown that Bcl-3 is able to
suppress p53 activation and apoptosis after DNA
damage [12]. This discrepancy could be due to the fact
that HeLa cervical cell line express the papillomavirus
E6 oncoprotein, which destabilizes p53 and, therefore,
should be resistant to the apoptotic effects of Bcl-3 [13].
This result excluded cell death as the mechanism for
the observed effect of Bcl-3 on the growth and clono-
genic survival of HeLa cells. Nevertheless, further ana-
lyses showed that depletion of Bcl-3 rendered cells more
sensitive to stress-induced apoptosis (Fig. 1D and Addi-
tional file 2, Fig. S2 A and C).
In order to investigate the possible mechanism of the
decreased growth, we followed Bcl-3 knockdown cells
and found, surprisingly, that more population doubling
resulted in an increasing number of multinucleated
cells, as assessed by fluorescent nuclear staining (Fig.
2a). The increase in multinuclear cells reached statistical
significance after five passages (Fig. 2c). To assess if the
changes were progressive and to provide additional sup-
port using a different expression approach, HeLa cells
were transfected with plasmids encoding sequences for
Bcl-3 and control shRNAs and followed for several
Figure 1 Knockdown of Bcl-3 in HeLa cervical cancer cells. HeLa cells were infected with retroviral particles packaged with constructs
derived from pSIREN vector (Clontech). These vectors codifies for a double-stranded short hairpin RNA (shRNA) directed toward Bcl-3 under the
human U6 promoter. Cells were selected with puromycin for 1 week and protein (upper panel A) or RNA (lower panel A) analyzed. B) HeLa cells
were grown in DMEM plus 8% fetal bovine serum for the times shown and viability assessed with the crystal violet method. Mean and standard
deviation of the optical absorbance are shown. Black bars: cells expressing a control (scrambled) shRNA, white bars: cells expressing a Bcl-3
shRNA. C) Clonogenic assays. 2.5 × 10
3 cells were seeded in 100 mm petri dishes, cultivated for 16 days, fixed and stained with crystal violet.
Colonies were manually counted. D) HeLa cells were grown in DMEM plus 8% fetal bovine serum, exposed to ultraviolet B light (280 nm) for 45
seconds (≈ 300 J/m
2 ) and viability assessed by crystal violet staining 24 hours later. Mean and standard deviation of the optical absorbance are
shown. Black bars: cells expressing a control (scrambled) shRNA, white bars: cells expressing a Bcl-3 shRNA. All the assays were performed by
triplicate in three separated experiments. Ctrl: control. IB: Immunoblot. *p < 0.05, **p < 0.01 using student’s T test.
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progressively from the culture (Fig. 2d), perhaps by dilu-
tion by non-transfected cells, thus precluding a more
detailed analysis of the phenotype. A more careful
examination using image analysis of fixed cells showed
that Bcl-3-depleted cells were not only polynuclear, but
also demonstrated a larger nuclear area (Fig. 2b). The
larger area is suggestive of an increased cellular ploidy
in Bcl-3-depleted cells. To investigate this possibility, we
performed karyotype analyses. Fig 3 shows that HeLa
cells are aneuploid by nature, with a chromosome num-
ber range between 55 and 140 and a modal number
between 51 and 60 (Fig. 3a). In sharp contrast, we found
that the downregulation of Bcl-3 induced an increase of
the chromosome number range to 55-280, with a modal
number between 101 and 120 (Fig. 3a). These results
clearly showed that Bcl-3 is a key regulator of mitosis in
HeLa cells.
Cell cycle checkpoints are essential for maintaining
genetic stability. In response to DNA damage, cells
arrest in G1/S or G2/M checkpoints for repair.
Extended arrest in the G2/M checkpoint after DNA
damage can induce centrosome amplification and failed
cytokinesis by ATM-dependent and -independent sig-
naling [13]. This phenomenon is thought to represent a
mechanism for ensuring the reproductive death of cells
that evade the spindle assembly checkpoint. To assess if
Bcl-3-depleted cells were, indeed, arrested at the G2/M
checkpoint, we performed flow cytometric analyses and
found a significant increase in this population of cells
relative to the control (Fig. 3b). In addition, we found a
progressive increase in the mitotic index (4.27% in
Figure 2 Bcl-3 knockdown cells are multinucleated. A) Nuclei of HeLa cells expressing a control shRNA (left panels) or Bcl-3 shRNA (right
panels) as described in Fig. 1 were stained with ethidium bromide after five population doublings. Arrow shows a multinuclear cell. B) Box-and-
whisker plots of nuclear area from a thousand nuclei of HeLa cells expressing a control shRNA or Bcl-3 shRNA as described in Fig. 1. Nuclei were
stained with ethidium bromide. These results were obtained in the described cells after five population doublings. The plots show quartiles,
sample minimum and maximum. *p < 0.01 by Wilcoxon rank test. C) Table showing the percentage and standard deviation of mono, bi or
multinuclear cells derived from two hundred cells counted in three different preparations of the described cells after five population doublings.
D) HeLa cells were transiently transfected with a plasmid encoding a shRNA directed toward Bcl-3 and, along, the ZsGreen protein marker
(plasmid pSIREN-RetroQ-ZsGreen, Clontech; CA, USA) (Bcl3). As control, a plasmid with encodes a scrambled shRNA and the same marker, was
transfected (Ctrl). After 5, 12 or 18 population doublings (PD), green multinuclear cells were counted (percentage at the bottom) n.d.: not
detected. RNA was also isolated from these passages and assayed for Bcl-3 expression by RT-PCR. Note that at the 18
th PD, the Bcl-3 knockdown
effect was lost. Transfection efficiency was approximately 30%. The differences observed between the experiments in Fig. 1 and 2 were probably
due to the lower efficiency of the knockdown strategy used (infection versus transfection).
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population doublings; 3.00% in control cells versus
10.41% in cells deficient for Bcl-3 at 18 population dou-
blings). To provide further insight, we then analyzed
cells transiently-transfected with a plasmid that
expresses a Bcl3 shRNA and a green fluorescent marker
(EGFP). Fig 3E shows that Bcl-3 depletion increased the
number of cells in pro-metaphase and metaphase, sug-
gesting that the multinucleation effect may be mediated
by a faliure to satisfy the spindle assembly checkpoint.
In support of this result, we found that cyclin-dependent
kinase 1 (Cdk1) was hypophosphorylated and cyclin B
expression increased in Bcl-3-depleted cells, a result
consistent with the mitosis-promoting effect of this
Figure 3 Increased ploidy and centrosome amplification in Bcl-3-depleted cells. A) Histogram showing HeLa cells stably expressing control
(black bars) or Bcl-3 (white bars) shRNAs were treated with colcemide and subjected to a karyotype analysis. Careful examination of fifty
karyograms was perfomed and chromosome counts obtained. B) Table showing percentage and standard deviation of cell populations in G1, S
and G2/M examined by flow cytometry analysis. C) HeLa cells stably expressing control or Bcl-3 shRNAs stained with an anti- gamma tubulin
antibody and visualized using fluorescence microscopy. The graph shows percentage of control (black bars) or Bcl-3-depleted (white bars) cells
with 2, 3 or more than three centrosomes at mitosis. Two hundred and fifty fields were scored in three independent experiments. * p = 0.02;
**p = 0.04 by Student’s T test. Inset: representative image. Arrows show centrosomes. D) Western blot analyses of cell with downregulated Bcl-3
levels. E) Effect of the expression of a Bcl3 shRNA in the number of HeLa cells at the indicated cell cycle phase (number of cells/4000 cells). The
cells were transfected with a plasmid that direct the expression of a Bcl3 or a control shRNA and, simultaneously, an Enhanced Green
Fluorescent Protein as a marker. After 48 hours, the cells were stained with an antibody directed toward g-tubulin, a Cy5-marked secondary
antibody and DAPI. Phases were scored only from green cells and results were pooled from three separate experiments. P: Prometaphase, M:
Metaphase, A: Anaphase, T: Telophase, C: Cytokinesis.
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induce centrosome amplification, we stained the mitotic
spindles using a tubulin antibody. As shown in Fig 3c,
cells with downregulated Bcl-3 demonstrated a signifi-
cant increase in centrosome numbers, thus, corroborat-
ing the amplification of centrosomes at mitosis. As
expected, no differences were found at interphase in
centrosome numbers (70% with 2 centrosomes and 30%
with 1 centrosome in both Bcl-3 defficient and control
cells). Finally, we assessed whether Bcl-3 depletion could
induce a DNA damage response. As shown in Fig 3d,
Western blot analysis demonstrated an increase in the
phosphorylation of histone 2AX, a marker of DNA
damage [14], as well as increased phosphorylation of the
kinase responsible for this modification, ATM, in Bcl-3-
depleted cells. Interestingly, phosphorylation of Chk1,
an essential serine/threonine kinase required for the cell
cycle checkpoint arrest after DNA damage [15], was
reduced by Bcl-3 depletion. These results showed that
Bcl-3 downregulation induces a DNA damage response
that is uncoupled from the checkpoint-mediated cell
cycle arrest.
Cancer cells frequently show amplification of centro-
some number and aneuploidy. It has been shown that
both processes could be linked to tumor progression,
tumor regrowth and drug resistance [16]. Centrosome
numeric aberrations arise as a consequence of failures in
cytokinesis, which can be induced by abnormalities in
the expression or regulation of several protein kinases
and multiple genetic aberrations, in particular the loss
of the tumor suppressor, p53 [17]. In this regard, it is
thought that cumulative DNA damage or mutations in
DNA repair genes are responsible for this phenomenon
[18]. The presence of cancer cells with more than two
centrosomes in clinical samples suggests the existence
of mechanisms that allow cells to survive despite this
amplification. In the present paper, we provide evidence
that the depletion of Bcl-3 expression is associated with
centrosome amplification and an endopolyploid pheno-
type. This phenotype could be due to a direct effect of
this oncogene on centrosome amplification and cytokin-
esis aberrations or could be indirectly caused by an
undescribed cell death function. In the latter case, the
effects of Bcl-3 depletion should be due to the accumu-
lation of aberrant cells in the culture. This is unlikely
since we did not find evidence of increased cell death,
and the growth and clonogenic potential of Bcl-3-
depleted cells were also decreased. Alternatively, Bcl-3
could participate in the genesis of centrosome amplifica-
tion and cytokinesis aberrations by disrupting the DNA
damage response. This theory is supported by the find-
ings of Boulton et al., who showed that the C. elegans
Bcl-3 ortholog is involved in the DNA damage response
[19]. In addition, Watanabe et al. showed that Bcl-3
binds to B3BP, a polynucleotide kinase with a MutS-
related domain, which is thought to be involved in DNA
repair [20]. Since Bcl-3 knockout mice do not show any
gross defect in DNA damage response, the participation
of this oncogene should be specific to cancer cells and
probably requires de novo overexpression.
Recently, it has been postulated that the oncogenic
potential of Bcl-3 could be related to the capacity of this
proto-oncogene to suppress p53 activation. This finding
implies that Bcl-3 action should be restricted to tumors
harboring no p53 alterations. Although not exhaustively
examined, our analyses of cultured cell lines do not
show a correlation between p53 mutation status and
Bcl-3 expression (Additional file 3, Fig. S3). In addition,
the cell lines used in this study were derived from HeLa
cells, which express papillomavirus protein E6 and, thus,
have a disrupted p53 signaling pathway. Thus, Bcl-3
oncogenic potential could not only be limited to its
effects on p53 activation, but to its effects on limiting
cell cycle and chromosomal number abnormalities in
p53-mutant cells. Additional experiments in mouse
models are needed to explore this hypothesis.
In conclusion, the present paper shows that the deple-
tion of Bcl-3 in cancer cells induces centrosome amplifi-
cation and increases ploidy. Bcl-3 may be needed to
overcome the deleterious effect of DNA damage on can-
cer cells with aberrant mitosis, and the importance of
Bcl-3 could be exploited for the development of selec-
tive inhibitors of tumorigenesis.
Additional material
Additional file 1: Figure S1. Morphology of MCF-7 Breast Cancer
cells expressing a Bcl-3 shRNA. Breast cancer cells present a similar
morphology to HeLa cells after Bcl-3 depletion.
Additional file 2: Figure S2. Effects of Bcl-3 depletion on apoptosis.
Cells with Bcl-3 knockdown are more susceptible to apoptosis induced
by ultraviolet light, as assessed by nuclear morphology, viability assays
and TUNEL.
Additional file 3: Figure S3. Analysis of Bcl-3 mRNA expression of
breast cancer cell lines by RT-PCR. Bcl-3 steady-state levels in breast
cancer cell lines with different p53 status (wild type or mutated) and
expression.
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